Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton'...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® (...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the first presentation of data from the Phase 2 waveLINE-007 trial evalu...
Kite, a Gilead Company (Nasdaq: GILD), announced findings from three new analyses for Yescarta ® (axicabtagene ciloleucel) that demonstrate i...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced data from a five-year follow-up of the pivotal Phase III POLARIX study evalu...
- Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying patholo...
OmniScience and INmune Bio announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer&...
T cell isolation and controlled release delivers flexibility and control in process development, clinical trials and commercial manufacturing Ther...
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorex...
At AWS re:Invent, Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that LG AI Research, the artificial intelligence (...
Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors...
MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, announced a partnership with...
Amgen (NASDAQ:AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 ZENITH study evaluating WINREV...
© 2025 Biopharma Boardroom. All Rights Reserved.
